Abstract
The global pandemic of diabetes mellitus portends an alarming rise in the prevalence of microvascular complications, despite advanced therapies for hyperglycemia, hypertension and dyslipidemia. Peroxisome proliferator-activated receptor α (PPARα) is expressed in organs affected by diabetic microvascular disease (retina, kidney and nerves), and its expression is regulated specifically in these tissues. Experimental evidence suggests that PPARα activation attenuates or inhibits several mediators of vascular damage, including lipotoxicity, inflammation, reactive oxygen species generation, endothelial dysfunction, angiogenesis and thrombosis, and thus might influence intracellular signaling pathways that lead to microvascular complications. PPARα has emerged as a novel target to prevent microvascular disease, via both its lipid-related and lipid-unrelated actions. Despite strong experimental evidence of the potential benefits of PPARα agonists in the prevention of vascular damage, the evidence from clinical studies in patients with diabetes mellitus remains limited. Promising findings from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study on microvascular outcomes are countered by elevations in participants' homocysteine and creatinine levels that might potentially attenuate the benefits of PPARα activation. This Review focuses on the role of PPARα activation in diabetic microvascular disease and highlights the available experimental and clinical evidence from studies of PPARα agonists.
Key Points
-
Activation of peroxisome proliferator-activated receptor α (PPARα) alleviates dyslipidemia and might slow the progression of diabetic microvascular complications through both lipid-related and lipid-unrelated mechanisms
-
Substantial experimental evidence shows that PPARα activation decreases reactive oxygen species generation and inflammatory cytokine expression through both lipid-related and lipid-unrelated effects
-
The influence of PPARα activation on endothelial function remains unresolved, probably owing to species-related differences in PPARα activity and the diversity of regulators of endothelial function
-
Although fenofibrate reduced the need for amputations and laser treatment (albeit without preserving visual acuity) in patients with retinopathy, fibrates cannot yet be recommended for prevention of diabetic microvascular complications
-
Increased serum levels of creatinine, cystatin C and homocysteine during fibrate therapy might reflect a transient impairment of renal function, potentially related to effects of fibrates on renal hemodynamics
-
Large-scale, prospective, randomized trials to evaluate the efficacy of fibrates on microvascular outcomes as primary end points in patients with diabetes mellitus are urgently needed
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005).
Gaede, P., Lund-Andersen, H., Parving, H. H. & Pedersen, O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580–591 (2008).
Kilpatrick, E. S., Rigby, A. S. & Atkin, S. L. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32, 1901–1903 (2009).
[No authors listed] Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 47, 1703–1720 (1995).
Bilous, R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet. Med. 25 (Suppl. 2), 25–29 (2008).
Kohner, E. M. Microvascular disease: what does the UKPDS tell us about diabetic retinopathy? Diabet. Med. 25 (Suppl. 2), 20–24 (2008).
Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).
Monti, M. C. et al. Familial risk factors for microvascular complications and differential male–female risk in a large cohort of American families with type 1 diabetes. J. Clin. Endocrinol. Metab. 92, 4650–4655 (2007).
Freedman, B. I., Bostrom, M., Daeihagh, P. & Bowden, D. W. Genetic factors in diabetic nephropathy. Clin. J. Am. Soc. Nephrol. 2, 1306–1316 (2007).
Fioretto, P., Dodson, P. M., Ziegler, D. & Rosenson, R. S. Residual microvascular risk in diabetes: unmet needs and future directions. Nat. Rev. Endocrinol. 6, 19–25 (2010).
Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005).
Lefebvre, P., Chinetti, G., Fruchart, J. C. & Staels, B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J. Clin. Invest. 116, 571–580 (2006).
Biscetti, F. et al. Peroxisome proliferator-activated receptors and angiogenesis. Nutr. Metab. Cardiovasc. Dis. 19, 751–759 (2009).
Nakagawa, T., Kosugi, T., Haneda, M., Rivard, C. J. & Long, D. A. Abnormal angiogenesis in diabetic nephropathy. Diabetes 58, 1471–1478 (2009).
Ruan, X. Z., Varghese, Z. & Moorhead, J. F. An update on the lipid nephrotoxicity hypothesis. Nat. Rev. Nephrol. 5, 713–721 (2009).
Goldberg, R. B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 94, 3171–3182 (2009).
Sourris, K. C. & Forbes, J. M. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy—are these receptors valid therapeutic targets. Curr. Drug Targets 10, 42–50 (2009).
Williams, M. D. & Nadler, J. L. Inflammatory mechanisms of diabetic complications. Curr. Diab. Rep. 7, 242–248 (2007).
Navarro-González, J. F. & Mora-Fernández, C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 19, 433–442 (2008).
Tuttle, K. R. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J. Am. Soc. Nephrol. 16, 1537–1538 (2005).
Gurley, S. B. & Coffman, T. M. The renin–angiotensin system and diabetic nephropathy. Semin. Nephrol. 27, 144–152 (2007).
Kang, Y. S. et al. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol. Dial. Transplant. 24, 73–84 (2009).
Quattrini, C., Jeziorska, M., Boulton, A. J. & Malik, R. A. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care 31, 140–145 (2008).
Mount, P. F. & Power, D. A. Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol. (Oxf.) 187, 433–446 (2006).
Toda, N. & Nakanishi-Toda, M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog. Retin. Eye Res. 26, 205–238 (2007).
Johnstone, M. T. et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88, 2510–2516 (1993).
Williams, S. B., Cusco, J. A., Roddy, M. A., Johnstone, M. T. & Creager, M. A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 27, 567–574 (1996).
Levy, D. & Zochodne, D. W. NO pain: potential roles of nitric oxide in neuropathic pain. Pain Pract. 4, 11–18 (2004).
Dogra, G., Rich, L., Stanton, K. & Watts, G. F. Endothelium-dependent and independent vasodilation studies at normoglycemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 44, 593–601 (2001).
Nguyen, T. T. et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care 32, 1704–1709 (2009).
Astrup, A. S. et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate. Diabetes Care 31, 1170–1176 (2008).
Lopes-Virella, M. F. et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 31, 2006–2012 (2008).
Garbarino, J. & Sturley, S. L. Saturated with fat: new perspectives on lipotoxicity. Curr. Opin. Clin. Nutr. Metab. Care 12, 110–116 (2009).
Tikhonenko, M. et al. Remodeling of retinal fatty acids in an animal model of diabetes: a decrease in long chain polyunsaturated fatty acids is associated with a decrease in fatty acid elongases Elovl2 and Elovl4. Diabetes 59, 219–227 (2010).
Lyons, T. J., Li, W., Wells-Knecht, M. C. & Jokl, R. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes 43, 1090–1095 (1994).
Fredrikson, G. N. et al. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia 52, 1426–1433 (2009).
Sapieha, P. et al. Proliferative retinopathies: angiogenesis that blinds. Int. J. Biochem. Cell Biol. 42, 5–12 (2010).
Chowdhury, T. A., Hopkins, D., Dodson, P. M. & Vafidis, G. C. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye (Lond.) 16, 689–693 (2002).
Simó, R. & Hernández, C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care 32, 1556–1562 (2009).
Kasiske, B. L., O'Donnell, M. P., Cleary, M. P. & Keane, W. F. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 33, 667–672 (1988).
Wiggin, T. D. et al. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58, 1634–1640 (2009).
Vincent, A. M. et al. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 58, 2376–2385 (2009).
Klein, B. E., Moss, S. E., Klein, R. & Surawicz, T. S. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98, 1261–1265 (1991).
van Leiden, H. A. et al. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch. Ophthalmol. 121, 245–251 (2003).
Chew, E. Y. et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch. Ophthalmol. 114, 1079–1084 (1996).
Colhoun, H. M. et al. Risk factors for renal failure: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44 (Suppl. 2), S46–S53 (2001).
Cusick, M. et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int. 66, 1173–1179 (2004).
Mulec, H., Johnsen, S. A., Wiklund, O. & Björck, S. Cholesterol: a renal risk factor in diabetic nephropathy? Am. J. Kidney Dis. 22, 196–201 (1993).
Thomas, M. C. et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 29, 317–322 (2006).
Tolonen, N. et al. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia 52, 2522–2530 (2009).
Maser, R. E. et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 38, 1456–1461 (1989).
Kempler, P. et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet. Med. 19, 900–909 (2002).
Tesfaye, S. et al. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 352, 341–350 (2005).
Wang, F. et al. Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol. Can. J. Physiol. Pharmacol. 86, 465–471 (2008).
Guan, Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 15, 2801–2815 (2004).
Portilla, D. Energy metabolism and cytotoxicity. Semin. Nephrol. 23, 432–438 (2003).
Cullingford, T. E. et al. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor α, β, and γ and the retinoid X receptor α, β, and γ in rat central nervous system. J. Neurochem. 70, 1366–1375 (1998).
Deplanque, D. et al. Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23, 6264–6271 (2003).
Bento-Abreu, A., Tabernero, A. & Medina, J. M. Peroxisome proliferator-activated receptor-α is required for the neurotrophic effect of oleic acid in neurons. J. Neurochem. 103, 871–881 (2007).
Xu, J., Racke, M. K. & Drew, P. D. Peroxisome proliferator-activated receptor-α agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J. Neurochem. 103, 1801–1810 (2007).
Leisewitz, A. V., Urrutia, C. R., Martinez, G. R., Loyola, G. & Bronfman, M. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis. J. Cell. Physiol. 217, 367–376 (2008).
Feng, D., Zhang, Y. & Chen, G. Cortical expression of peroxisome proliferator-activated receptor-α after human brain contusion. J. Int. Med. Res. 36, 783–791 (2008).
Poynter, M. E. & Daynes, R. A. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor κB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273, 32833–32841 (1998).
Delerive, P. et al. Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J. Biol. Chem. 274, 32048–32054 (1999).
Meissner, M. et al. PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ. Res. 94, 324–332 (2004).
Fisslthaler, B. & Fleming, I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ. Res. 105, 114–127 (2009).
Kim, J. et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp. Eye Res. 84, 886–893 (2007).
Goya, K. et al. Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24, 658–663 (2004).
Marx, N., Sukhova, G. K., Collins, T., Libby, P. & Plutzky, J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99, 3125–3131 (1999).
Okayasu, T., Tomizawa, A., Suzuki, K., Manaka, K. & Hattori, Y. PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation. Life Sci. 82, 884–891 (2008).
Blanco-Rivero, J. et al. Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway. Cardiovasc. Res. 75, 398–407 (2007).
Hostetler, H. A., Petrescu, A. D., Kier, A. B. & Schroeder, F. Peroxisome proliferator-activated receptor α interacts with high affinity and is conformationally responsive to endogenous ligands. J. Biol. Chem. 280, 18667–18682 (2005).
Rojas, C. V. et al. Long-term n-3 FA deficiency modifies peroxisome proliferator-activated receptor β mRNA abundance in rat ocular tissues. Lipids 37, 367–374 (2002).
Puskás, L. G. et al. Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain. Biochimie 86, 817–824 (2004).
San Giovanni, J. P. & Chew, E. Y. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog. Retin. Eye Res. 24, 87–138 (2005).
Balakumar, P., Chakkarwar, V. A. & Singh, M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol. Cell. Biochem. 320, 149–162 (2009).
Park, C. W. et al. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 69, 1511–1517 (2006).
Park, C. W. et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor α. Diabetes 55, 885–893 (2006).
Kamijo, Y. et al. Identification of functions of peroxisome proliferator-activated receptor α in proximal tubules. J. Am. Soc. Nephrol. 13, 1691–1702 (2002).
Xu, J., Chavis, J. A., Racke, M. K. & Drew, P. D. Peroxisome proliferator-activated receptor-α and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J. Neuroimmunol. 176, 95–105 (2006).
Mishra, R., Emancipator, S. N., Miller, C., Kern, T. & Simonson, M. S. Adipose differentiation-related protein and regulators of lipid homeostasis identified by gene expression profiling in the murine db/db diabetic kidney. Am. J. Physiol. Renal Physiol. 286, F913–F921 (2004).
Ledwith, B. J. et al. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells. J. Biol. Chem. 272, 3707–3714 (1997).
Wilson, M. W. et al. Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid. Arch. Toxicol. 69, 491–497 (1995).
Yoshinari, M. et al. Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with type 2 diabetes. Diabetes Res. Clin. Pract. 42, 149–154 (1998).
Hao, C. M. & Breyer, M. D. Physiological regulation of prostaglandins in the kidney. Annu. Rev. Physiol. 70, 357–377 (2008).
Chen, Y. J. & Quilley, J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release. J. Pharmacol. Exp. Ther. 324, 658–663 (2008).
Ansquer, J. C. et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am. J. Kidney Dis. 51, 904–913 (2008).
Forsblom, C. et al. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 33, 215–220 (2010).
Hottelart, C., El Esper, N., Rose, F., Achard, J. M. & Fournier, A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92, 536–541 (2002).
Yi, F. & Li, P. L. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am. J. Nephrol. 28, 254–264 (2008).
Maron, B. A. & Loscalzo, J. The treatment of hyperhomocysteinemia. Annu. Rev. Med. 60, 39–54 (2009).
Dierkes, J., Westphal, S. & Luley, C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 354, 219–220 (1999).
Taskinen, M. R. et al. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler. Thromb. Vasc. Biol. 29, 950–955 (2009).
Dayal, S. et al. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am. J. Physiol. Heart Circ. Physiol. 295, H816–H825 (2008).
Loscalzo, J. Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology. J. Clin. Invest. 119, 3203–3205 (2009).
Dayal, S. & Lentz, S. R. Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals. Antioxid. Redox Signal. 9, 1899–1909 (2007).
Legendre, C. et al. Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARα-mediated effect. Biochem. Biophys. Res. Commun. 295, 1052–1056 (2002).
Yideng, J. et al. Homocysteine-mediated PPARα, γ DNA methylation and its potential pathogenic mechanism in monocytes. DNA Cell Biol. 27, 143–150 (2008).
Mikael, L. G., Genest, J. Jr & Rozen, R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ. Res. 98, 564–571 (2006).
Michalik, L., Desvergne, B. & Wahli, W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat. Rev. Cancer 4, 61–70 (2004).
Peters, J. M., Cheung, C. & Gonzalez, F. J. Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand? J. Mol. Med. 83, 774–785 (2005).
Panigrahy, D. et al. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl Acad. Sci. USA 105, 985–990 (2008).
Hiukka, A. et al. Long-term effects of fenofibrate on carotid intima–media thickness and augmentation index in subjects with type 2 diabetes mellitus. J. Am. Coll. Cardiol. 52, 2190–2197 (2008).
Hogue, J. C. et al. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism 57, 380–386 (2008).
Rosenson, R. S., Wolff, D. A., Huskin, A. L., Helenowski, I. B. & Rademaker, A. W. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30, 1945–1951 (2007).
Desideri, G. et al. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J. Clin. Endocrinol. Metab. 88, 5341–5347 (2003).
Playford, D. A., Watts, G. F., Best, J. D. & Burke, V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am. J. Cardiol. 90, 1254–1257 (2002).
Playford, D. A., Watts, G. F., Croft, K. D. & Burke, V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 168, 169–179 (2003).
Evans, M. et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101, 1773–1779 (2000).
Avogaro, A. et al. Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. Eur. J. Clin. Invest. 31, 603–609 (2001).
Scott, R. et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32, 493–498 (2009).
Kohner, E. M. & Oakley, N. W. Diabetic retinopathy. Metabolism 24, 1085–1102 (1975).
Keech, A. C. et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370, 1687–1697 (2007).
Ansquer, J. C., Foucher, C., Aubonnet, P. & Le Malicot, K. Fibrates and microvascular complications in diabetes—insight from the FIELD study. Curr. Pharm. Des. 15, 537–552 (2009).
Ansquer, J. C. et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45, 485–493 (2005).
Smulders, Y. M. et al. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur. J. Clin. Invest. 27, 997–1002 (1997).
Nagai, T., Tomizawa, T., Nakajima, K. & Mori, M. Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. J. Atheroscler. Thromb. 7, 91–96 (2000).
Rajamani, K. et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373, 1780–1788 (2009).
Tanne, D. et al. C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. Stroke 37, 1720–1724 (2006).
Buse, J. B. et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am. J. Cardiol. 99, 21i–33i (2007).
Lalloyer, F. & Staels, B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler. Thromb. Vasc. Biol. 30, 894–899 (2010).
Acknowledgements
M. Maranghi holds a fellowship from Sapienza University, Rome, Italy. We thank Laura Impivaara for excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N. Matikainen declares that she has acted as a consultant for Novartis and Orion. M.-R.Taskinen declares that she has acted as a consultant for Kowa, Merck Sharpe & Dohme, and Novartis, received grant or research support from Eli Lilly, Merck Sharpe & Dohme, Sanofi-Aventis and Takeda, and is a member of the speakers' bureau or has received honoraria from Merck Sharpe & Dohme and Merck Schering-Plough. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Hiukka, A., Maranghi, M., Matikainen, N. et al. PPARα: an emerging therapeutic target in diabetic microvascular damage. Nat Rev Endocrinol 6, 454–463 (2010). https://doi.org/10.1038/nrendo.2010.89
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.89
This article is cited by
-
Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
Cardiovascular Diabetology (2021)
-
Emerging insights into the relationship between hyperlipidemia and the risk of diabetic retinopathy
Lipids in Health and Disease (2020)
-
A dietary anthocyanin cyanidin-3-O-glucoside binds to PPARs to regulate glucose metabolism and insulin sensitivity in mice
Communications Biology (2020)
-
PPARα activation directly upregulates thrombomodulin in the diabetic retina
Scientific Reports (2020)
-
Fenofibrate prevents iron induced activation of canonical Wnt/β-catenin and oxidative stress signaling in the retina
npj Aging and Mechanisms of Disease (2020)